文献速递消化系统肿瘤

氟尿嘧啶联合亚叶酸钙、伊立替康和奥沙利铂方案治疗初治转移性结直肠癌患者的随机对照试验

A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer.
PubMed 文献 · J Clin Oncol · 2023-01-01

该随机对照试验纳入795例初治转移性结直肠癌患者,比较IFL、FOLFOX和IROX三种两药方案的疗效与毒性。FOLFOX的中位疾病进展时间8.7个月、缓解率45%、中位生存期19.5个月,均显著优于IFL和IROX。FOLFOX严重恶心、呕吐、腹泻、发热性中性粒细胞减少和脱水发生率显著更低。

要点

  • FOLFOX中位疾病进展时间8.7个月、缓解率45%、中位生存期19.5个月
  • FOLFOX上述终点均显著优于IFL(6.9个月、31%、15.0个月)
  • 含奥沙利铂方案感觉神经病变和中性粒细胞减少更常见

核心结论

  • FOLFOX方案(奥沙利铂联合输注氟尿嘧啶加亚叶酸钙)有效且相对安全,应被视为晚期结直肠癌的标准治疗。

研究设计与样本

  • 随机对照试验,1999年5月至2001年4月共随机分配795例初治转移性结直肠癌患者。
  • 患者同时随机接受IFL(伊立替康联合推注氟尿嘧啶加亚叶酸钙,对照方案)、FOLFOX(奥沙利铂联合输注氟尿嘧啶加亚叶酸钙)或IROX(伊立替康联合奥沙利铂)。
  • 主要终点为疾病进展时间,次要终点为缓解率、生存时间和毒性。

主要发现

  • FOLFOX中位疾病进展时间8.7个月、缓解率45%、中位生存期19.5个月。
  • IFL中位疾病进展时间6.9个月、缓解率31%、中位生存期15.0个月;FOLFOX在所有终点上均显著优于IFL。
  • IROX中位疾病进展时间6.5个月、缓解率35%、中位生存期17.4个月;FOLFOX在疾病进展时间和缓解方面显著优于IROX。
  • FOLFOX严重恶心、呕吐、腹泻、发热性中性粒细胞减少和脱水的发生率显著更低。
  • 含奥沙利铂方案的感觉神经病变和中性粒细胞减少更常见。

关键数值与推荐

  • FOLFOX:中位疾病进展时间8.7个月,缓解率45%,中位生存期19.5个月。
  • IFL:中位疾病进展时间6.9个月,缓解率31%,中位生存期15.0个月。
  • IROX:中位疾病进展时间6.5个月,缓解率35%,中位生存期17.4个月。

临床怎么用

  • 作者认为FOLFOX方案应被视为晚期结直肠癌的标准治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Three agents with differing mechanisms of action are available for treatment of advanced colorectal cancer: fluorouracil, irinotecan, and oxaliplatin. In this study, we compared the activity and toxicity of three different two-drug combinations in patients with metastatic colorectal cancer who had not been treated previously for advanced disease. PATIENTS AND METHODS: Patients were concurrently randomly assigned to receive irinotecan and bolus fluorouracil plus leucovorin (IFL, control combination), oxaliplatin and infused fluorouracil plus leucovorin (FOLFOX), or irinotecan and oxaliplatin (IROX). The primary end point was time to progression, with secondary end points of response rate, survival time, and toxicity. RESULTS: A total of 795 patients were randomly assigned between May 1999 and April 2001. A median time to progression of 8.7 months, response rate of 45%, and median survival time of 19.5 months were observed for FOLFOX. These results were significantly superior to those observed for IFL for all end points (6.9 months, 31%, and 15.0 months, respectively) or for IROX (6.5 months, 35%, and 17.4 months, respectively) for time to progression and response. The FOLFOX regimen had significantly lower rates of severe nausea, vomiting, diarrhea, febrile neutropenia, and dehydration. Sensory neuropathy and neutropenia were more common with the regimens containing oxaliplatin. CONCLUSION: The FOLFOX regimen of oxaliplatin and infused fluorouracil plus leucovorin was active and comparatively safe. It should be considered as a standard therapy for patients with advanced colorectal cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Goldberg RM, Sargent DJ, Morton RF, et al. A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer. J Clin Oncol. 2023. PMID: 37379691. doi:10.1200/JCO.22.02759

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。